RxDoctor Payments DataLook up a doctor →

Ruemu Birhiray, MD

Hematology & Oncology · Indianapolis, INNPI 1295735058

Payments from drug & device makers

$3,950,250in general payments, 2019–2025

Across 3,782 payments — averaging $1044.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$434K
  • Johnson & Johnson$429K
  • Takeda Pharmaceuticals U.S.A., Inc.$278K
  • Novartis$247K
  • AstraZeneca$247K
  • Amgen$237K
  • plus $2.1M from 54 others
$3,976in research payments, 2019–2025

Across 10 payments — averaging $397.59 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$4K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Incyte Corporation399$434,070
Johnson & Johnson(2 entities)411$429,312
Takeda Pharmaceuticals U.S.A., Inc.97$277,951
Novartis191$246,738
AstraZeneca(2 entities)222$246,524
Amgen285$237,195
Lilly USA, LLC243$194,571
Regeneron47$175,987
Puma Biotechnology, Inc.126$168,476
Pharmacyclics LLC, An Abbvie Company128$130,700
Seagen Inc.84$122,648
Genentech, Inc.24$116,494
GSK83$106,004
Boehringer Ingelheim11$103,042
Exelixis Inc.76$86,560
E.r. Squibb & Sons, L.L.C.113$85,019
Sanofi100$77,876
Beigene USA, Inc.46$76,010
AbbVie80$68,608
Stemline Therapeutics Inc.53$65,549
Sobi, Inc40$56,088
Dova Pharmaceuticals25$44,986
Daiichi Sankyo Inc.71$39,470
Regeneron Healthcare Solutions, Inc.28$38,954
Taiho Oncology, Inc.17$34,917
Genmab U.S., Inc.72$23,650
Blueprint Medicines Corporation17$19,796
Astellas Pharma US Inc37$19,114
Beone Medicines USA, Inc.12$18,329
Gilead(2 entities)76$16,172
Sanofi US Services Inc.8$15,351
ADC Therapeutics America, Inc.11$14,902
Tesaro, Inc.16$13,661
Institut DE Recherches Internationales Servier3$13,405
Eli Lilly6$13,398
Karyopharm Therapeutics Inc.13$11,325
CTI Biopharma Corp.9$11,308
Pfizer99$10,980
Ipsen Biopharmaceuticals, Inc6$8,917
Pharmacosmos Therapeutics Inc.10$8,580
Morphosys, US Inc.14$8,054
Syndax Pharmaceuticals, Inc.3$7,335
Rigel Pharmaceuticals, Inc.17$6,842
Janssen Scientific Affairs, LLC7$6,772
Bayer10$5,227
Coherus Oncology, Inc.14$4,880
Astellas Pharma Global Development1$4,650
Genentech USA, Inc.38$4,513
Bristol Myers Squibb48$3,963
Invivyd Inc1$2,818
Novocure Inc.3$2,292
TG Therapeutics, Inc.1$2,025
Array Biopharma Inc21$997
Merck48$908
Spectrum Pharmaceuticals Inc.1$750
Boehringer Ingelheim International GmbH4$736
Tersera Therapeutics LLC10$717
Eisai Inc.28$523
Myriad Genetic Laboratories, Inc.3$494
Acrotech Biopharma Inc.20$315

How this compares

$3,950,250 in reported general payments places this provider in the 95th percentile of 224 hematology & oncology providers in Indiana.

See all hematology & oncology providers in Indiana →

Medicare billing

Part B allowed, 2024
$6,257,668
Medicare patients
1,032
Services billed
241,755

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Indianapolis

See the full list for Indiana →

Where these figures come from

Is this you, or does something look wrong? →